Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Clements

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
The Journal of Infectious Diseases|December 1, 1995
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and childrenR A Karron, P F Wright, F K Newman, et al.
AIDS (London, England)|May 1, 1994
Comparison of the immune response to recombinant gp120 in humans and chimpanzeesP W Berman, D J Eastman, D M Wilkes, et al.
Journal of Virology|February 1, 1988
Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccinesM H Snyder, R F Betts, D DeBorde, et al.
The Journal of Infectious Diseases|March 1, 1982
The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup O1 biotype El Tor isolated from sewage water in BrazilM M Levine, R E Black, M L Clements, et al.
Annals of Internal Medicine|January 15, 1991
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials NetworkR Dolin, B S Graham, S B Greenberg, et al.
AIDS Research and Human Retroviruses|December 1, 1994
Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials NetworkM C Keefer, B S Graham, R B Belshe, et al.
The Journal of Infectious Diseases|May 1, 1991
The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and childrenM C Steinhoff, N A Halsey, L F Fries, et al.
Journal of Clinical Microbiology|August 1, 1992
Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in childrenR B Belshe, R A Karron, F K Newman, et al.
Clinical and Experimental Immunology|November 1, 1994
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, D H Schwartz, B S Graham, et al.
The Journal of Infectious Diseases|October 1, 1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials NetworkB S Graham, G J Gorse, D H Schwartz, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
The Journal of Infectious Diseases|December 1, 1995
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and childrenR A Karron, P F Wright, F K Newman, et al.
AIDS (London, England)|May 1, 1994
Comparison of the immune response to recombinant gp120 in humans and chimpanzeesP W Berman, D J Eastman, D M Wilkes, et al.
Journal of Virology|February 1, 1988
Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccinesM H Snyder, R F Betts, D DeBorde, et al.
The Journal of Infectious Diseases|March 1, 1982
The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup O1 biotype El Tor isolated from sewage water in BrazilM M Levine, R E Black, M L Clements, et al.
Annals of Internal Medicine|January 15, 1991
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials NetworkR Dolin, B S Graham, S B Greenberg, et al.
AIDS Research and Human Retroviruses|December 1, 1994
Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials NetworkM C Keefer, B S Graham, R B Belshe, et al.
The Journal of Infectious Diseases|May 1, 1991
The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and childrenM C Steinhoff, N A Halsey, L F Fries, et al.
Journal of Clinical Microbiology|August 1, 1992
Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in childrenR B Belshe, R A Karron, F K Newman, et al.
Clinical and Experimental Immunology|November 1, 1994
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, D H Schwartz, B S Graham, et al.
The Journal of Infectious Diseases|October 1, 1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials NetworkB S Graham, G J Gorse, D H Schwartz, et al.
Pageof 13